Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

NCT02689219 is registered in ClinicalTrials.gov with Nabil Adra as lead sponsor.

NCT NCT02689219
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02689219 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Lead sponsor
Nabil Adra
Phase
Phase 2
Overall status
Terminated
Start date
March 9, 2016
Completion date
January 23, 2019
Enrollment
18 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

embryonal carcinoma, germ cell tumors, nonseminomatous germ cell tumor, testicular cancer, testis cancer